Abstract:
Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient. The pancreatic cells may be characterized as mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or a subtype thereof. Benign cells may be distinguished from pre-malignant or malignant pancreatic cells.
Abstract:
This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.